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Elimination of fukutin reveals cellular and molecular
pathomechanisms in muscular dystrophy-
associated heart failure
Yoshihiro Ujihara1,2,4, Motoi Kanagawa3, Satoshi Mohri1,2, Satomi Takatsu1, Kazuhiro Kobayashi3,
Tatsushi Toda3, Keiji Naruse 1 & Yuki Katanosaka 1*
Heart failure is the major cause of death for muscular dystrophy patients, however, the
molecular pathomechanism remains unknown. Here, we show the detailed molecular
pathogenesis of muscular dystrophy-associated cardiomyopathy in mice lacking the fukutin
gene (Fktn), the causative gene for Fukuyama muscular dystrophy. Although cardiac Fktn
elimination markedly reduced α-dystroglycan glycosylation and dystrophin-glycoprotein
complex proteins in sarcolemma at all developmental stages, cardiac dysfunction was
observed only in later adulthood, suggesting that membrane fragility is not the sole etiology
of cardiac dysfunction. During young adulthood, Fktn-deﬁcient mice were vulnerable to
pathological hypertrophic stress with downregulation of Akt and the MEF2-histone deace-
tylase axis. Acute Fktn elimination caused severe cardiac dysfunction and accelerated mor-
tality with myocyte contractile dysfunction and disordered Golgi-microtubule networks,
which were ameliorated with colchicine treatment. These data reveal fukutin is crucial for
maintaining myocyte physiology to prevent heart failure, and thus, the results may lead to
strategies for therapeutic intervention.
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The dystrophin-glycoprotein complex (DGC) links theintracellular cytoskeleton to the extracellular basementmembrane, thereby providing structural support for the
sarcolemma1,2. Within this complex, dystroglycan (DG) links
intracellular dystrophin to the extracellular matrix3. As heavily
glycosylated α-DG binds tightly and with high afﬁnity to lami-
nin4, a glycosylation deﬁciency can dissolve the
DGC–extracellular matrix connection. Mutations of dystrophin
and the transmembrane sarcoglycans result in Duchenne/Becker
and limb girdle muscular dystrophies, respectively4–7. Many
patients with muscular dystrophies, particularly those with
defects in the DGC, develop cardiomyopathies with chamber
dilation and myocardial dysfunction8–12, which is the major cause
of death in these patients.
Recently, the full functional glycan structure of α-DG required
for its ligand binding activities was identiﬁed13–15, providing
insight into the pathogenesis and therapeutic strategies for α-DG-
associated diseases, including Fukuyama-type congenital mus-
cular dystrophy (FCMD)16, muscle–eye–brain disease17,
Walker–Warburg syndrome18, congenital muscular dystrophy
types 1C and 1D19, and limb girdle muscular dystrophy type 2I20.
Although the causative genes for these diseases differ, one bio-
chemical feature that is common among them is abnormal gly-
cosylation of α-DG. Thus, these conditions are considered α-
DGpathies. FCMD is caused by mutation of the fukutin gene
(FKTN)16, which encodes a Golgi-based ribitol phosphate trans-
ferase that catalyzes the biosynthesis of tandem ribitol phosphate
structures on α-DG by sequential action with fukutin-related
protein (FKRP)13. Mutations in FKTN and FKRP-associated α-
DGpathy are both associated with cardiomyopathies21,22. How-
ever, the detailed molecular mechanisms for cardiac pathogenesis
in these conditions remain unknown.
In this study, we show a crucial role for FKTN in the main-
tenance of myocyte structure and function using cardiac-speciﬁc
Fktn knockout mice. The results from this study improve our
understanding of the pathomolecular mechanism underlying
muscular dystrophy-associated heart failure.
Results
Cardiac changes in MCK-Fktn-cKO (Fktnﬂox/ﬂox;MCK-Cre+/−)
mice. To examine the effect of FKTN deﬁciency, we crossed
Fktnﬂox/ﬂox (ﬂoxed) mice with a transgenic line expressing Cre
recombinase under the control of the MCK promoter23. The
reduced expression of FKTN and DGC proteins in the hearts of
these MCK-Fktn-cKO mice was conﬁrmed by immunoprecipi-
tation and immunoblotting (Supplementary Fig. 1a, b). The gly-
cosylated form of α-DG and DGC immunoreactivity increased in
the sarcolemma at 24 weeks after birth in normal control mice
(Fig. 1a), suggesting that the physiological contribution of DGC
proteins in the heart increases 6 months after birth. Notably,
FKTN deﬁciency not only resulted in a reduction of α-DG gly-
cosylation but also impaired the expression of DGC proteins in
the sarcolemma at all developmental stages (Fig. 1a). We next
examined global cardiac morphology and function in MCK-Fktn-
cKO mice at different time points after birth. Cardiac gross
morphology (Fig. 1b) and the heart-to-body weight ratio (Fig. 1c)
were maintained in mice with Fktn deﬁciency. However, the
cross-sectional areas of cardiomyocytes and ﬁbrosis were
increased in MCK-Fktn-cKO hearts 24–48 weeks after birth
(Fig. 1d–f). These mice also showed cardiac dysfunction and
chamber dilation during diastole at this age (Fig. 1g, h). Only one
or a few damaged areas were detected by anti-mouse IgG in 48-
week-old MCK-Fktn-cKO mice (Supplementary Fig. 2). The 48-
week-old heterozygous (Fktnﬂox/+; MCK-Cre+/−) mice showed
no abnormalities in overall cardiac morphology and function
(Supplementary Fig. 3). Thus, Fktn deﬁciency leads to patholo-
gical cardiac remodeling in 24–48-week-old mice.
Impaired myocyte function in 10-month-old MCK-Fktn-cKO
mice. The subcellular structure of cardiomyocytes and the loca-
lization of Ca2+ regulatory proteins are well suited to their cel-
lular functions24. Well-ordered patterns of immunoﬂuorescence
were observed for L-type Ca2+ channels (LTCC), Na+/Ca2+
exchanger 1 (NCX1), and ryanodine receptor 2 (RyR2) in normal
hearts (Fig. 2a, left) but not in 10-month-old MCK-Fktn-cKO
hearts (Fig. 2a, right), suggesting a defect in intracellular Ca2+
handling. The myoﬁlaments needed to generate force were
extensively disorganized in the MCK-Fktn-cKO hearts (Fig. 2b),
and cardiomyocytes from these hearts showed reduced short-
ening (Fig. 2c) and impaired Ca2+ handling during
excitation–contraction (E–C) coupling (Fig. 2d). This abnorm-
ality in Ca2+ cycling was most evident at 5 mM, the concentra-
tion at which Fktn-deﬁcient myocytes also showed reduced
amplitude (Fig. 2e), longer time constants (i.e., slower decay
speed) (Fig. 2f), and increased time to peak (Fig. 2g). As a result,
Ca2+ contents were lower in the sarcoplasmic reticula (SRs) of
MCK-Fktn-cKO myocytes than in those of ﬂoxed controls
(Fig. 2h). Thus, cardiac dysfunction in adult MCK-Fktn-cKO
mice occurred at the cardiomyocyte level.
Hypertrophic responses of hearts from MCK-Fktn-cKO mice.
As mentioned above, young-adult MCK-Fktn-cKO mice did not
exhibit signiﬁcant cardiac dysfunction under physiological con-
ditions (Fig. 1). Consistently, isolated cardiomyocytes from 10-
week-old MCK-Fktn-cKO mice showed normal contractility and
Ca2+ handling during E–C coupling (Supplementary Fig. 4). To
investigate the effect of FKTN deﬁciency under stress conditions,
we examined cardiac structure, function, and intracellular sig-
naling after inducing various hemodynamic stresses. Control
mice showed incremental changes in heart weight-to-body weight
ratios (Fig. 3a, b) and cross-sectional areas of cardiomyocytes
(Fig. 3c) without increased ﬁbrosis (Fig. 3d) after administration
of the adrenergic receptor agonists isoproterenol and pheny-
lephrine as well as after prolonged pressure overload via 2-week
thoracic aortic constriction. Conversely, these treatments caused
chamber dilation and ﬁbrosis with severe cardiac dysfunction in
the hearts of MCK-Fktn-cKO mice (Fig. 3a, d, e). These obser-
vations suggest that Fktn-deﬁcient hearts are vulnerable to
hypertrophic stress and that FKTN in the heart is essential for
compensatory hypertrophic responses against hemodynamic
stress.
Next, in order to understand the molecular basis underlying
vulnerability, we analyzed the changes in intracellular signaling in
the hearts of Fktn-deﬁcient mice treated with isoproterenol for
2 weeks. It is well known that Akt and Ca2+ calmodulin-
dependent protein kinase II (CamKII) phosphorylation mediate
myocyte survival and apoptotic/necrosis pathways25–27, respec-
tively. We found that isoproterenol increased the phosphorylation
of Akt in control hearts but not in Fktn-deﬁcient hearts, which
instead showed increased phosphorylation of CamKII, suggesting
a downregulation of survival and upregulation of apoptosis/
necrosis signaling. Thus, Fktn-deﬁcient hearts showed an
impaired hypertrophic response to stress.
It is also known that activation of protein kinase D (PKD) leads
to the phosphorylation of histone deacetylases (HDACs) in
myocyte pathological remodeling28–30. Whereas isoproterenol
treatment slightly induced the phosphorylation of PKD in control
hearts, basal levels of PKD phosphorylation in the absence of
isoproterenol were already signiﬁcantly higher in MCK-Fktn-cKO
hearts than in controls (Fig. 3f). Similarly, the phosphorylation of
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HDAC9 in control hearts was increased by isoproterenol
treatment, while the basal phosphorylation in MCK-Fktn-cKO
hearts was already extremely high. These data indicate that Fktn
elimination enhanced the PKD signaling pathways, provoking
HDAC9 nucleocytoplasmic shuttling under physiological condi-
tions. Therefore, Fktn elimination accelerates the progression
from compensated cardiac hypertrophy to heart failure under
hemodynamic stress conditions.
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Fig. 1 Cardiac change in MCK-Fktn-cKO (Fktnﬂox/ﬂox;MCK-Cre+/−) mice. a Representative immunoﬂuorescent images of DGC complex and glycosylation
form of α-DG in control (ﬂoxed) and MCK-Fktn-cKO hearts. Anti-IIH6 (glycosylated form of αDG), βDG, dystrophin (Dys), αSG, βSG, and γSG antibodies
(green) and DAPI (blue). Scale bar, 10 μm. b Cardiac morphology in ﬂoxed and MCK-Fktn-cKO mice. Scale bar, 5 mm. c Heart weight-to-body weight ratios
(HW/BW) (n= 9 mice per group). dMasson’s trichrome staining of the left ventricle. Scale bar, 50 μm. Cross-sectional areas (6w, n= 259 and 268 cells;
16w, n= 303 and 311 cells; 24w, n= 266 and 287 cells; 48w, n= 283 and 256 cells measured from 3 hearts per group.) (e) and ﬁbrosis percentages (n= 3
mice per group) (f) from parafﬁn sections of left ventricles. Echocardiographic parameters of left ventricle diastolic dimension (g) and fractional shortening
(h) in ﬂoxed and MCK-Fktn-cKO mice (n= 12 mice per group). Data are means ± s.e.m; #P < 0.05 between indicated groups based on Student’s t-tests.
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Impaired hypertrophic response in MCK-Fktn-cKO cardio-
myocytes. To more directly examine the hypertrophic responses
of MCK-Fktn-cKO cardiomyocytes, we analyzed cell growth
during culture with or without phenylephrine for 48 h. We con-
ﬁrmed successful Cre-lox recombination and expression of Cre
recombinase in the nucleus in cultured neonatal cardiomyocytes
from MCK-Fktn-cKO mice (Supplementary Fig. 5). We also
conﬁrmed reduction of FKTN protein in 1-d-old MCK-Fktn-cKO
mice (Supplementary Fig. 5). In the presence of phenylephrine,
cardiomyocytes from control mice showed enhanced sarcomere
organization and upregulation of NCX1 expression (Fig. 4a),
which are signs of myoﬁbril maturation and intracellular Ca2+
handling during E–C coupling24. By contrast, MCK-Fktn-cKO
cardiomyocytes treated with phenylephrine had immature and
tangled myoﬁlaments (Fig. 4b) and showed no increase in cell
area (Fig. 4c). We conﬁrmed that all cKO myocytes treated with
phenylephrine were alive using a LIVE/DEAD assay (Fig. 4d).
Remarkably, cKO myocytes did not show spontaneous hyper-
trophy (at 48 h in the absence of phenylephrine; Fig. 4c). These
myocytes exhibited no sarcomere formation, cell–cell interaction
(Fig. 4a, upper right panels), or spontaneous beating, suggesting
that Fktn deﬁciency also affects myocyte maturation in cKO cells.
Ca2+ content in the SRs of control cardiomyocytes increased
during culture with phenylephrine (Fig. 4e), whereas no such
increase was observed in cardiomyocytes from MCK-Fktn-cKO
mice. However, caffeine-induced release was still present, sug-
gesting that these cells had functions characteristic of cardio-
myocytes. As a control, mixed ﬁbroblasts in the cultured myocyte
preparation showed no response to caffeine (Fig. 4e). These
observations suggest that Fktn elimination in myocytes impairs
hypertrophic responses.
Using these cell models, we examined the subcellular
localization of MEF2, which acts with class IIa HDACs, such as
HDAC9, in myocyte differentiation and compensative hyper-
trophic responses31. MEF2 underwent nuclear translocation in
control cardiomyocytes but not in MCK-Fktn-cKO cardiomyo-
cytes cultured with 10% fetal calf serum (FCS) or 10 μM
phenylephrine for 48 h (Fig. 5a). In control cardiomyocytes,
serum (as well as adrenergic agonists) induced the nuclear export
of HDAC9, which relieves transcriptional repression28. This
phenomenon was not observed in MCK-Fktn-cKO cardiomyo-
cytes (Fig. 5b). These observations suggest that MEF2 and
HDAC9 translocation are impaired in FKTN-deﬁcient
cardiomyocytes.
Phosphatidylinositol 4-phosphate (PI4P) in the Golgi appara-
tus is required for PKD activation in pathological hypertrophic
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Fig. 2 Impaired myocyte function in 10-month-old MCK-Fktn-cKO (Fktnﬂox/ﬂox; MCK-Cre+/−) mice. a Representative immunostaining for NCX1, RyR2,
and LTCC (DAPI counterstain, blue) in hearts of 10-month-old mice. Scale bar, 100 μm. b Representative immunoﬂuorescence (top: phalloidin, red; DAPI,
blue (scale bar, 100 μm)) and electron microscopy (scale bar, 5 μm (middle) and 1 μm (lower)) images of myoﬁlaments. c Frequency-dependent
shortening of cardiomyocytes (n= 16 and 20 cells measured from 4 and 5 hearts, respectively). #P < 0.05 vs. ﬂoxed mice based on Student’s t-tests.
(d) Indo-1 ﬂuorescence in single cardiomyocytes stimulated at 1 Hz (1.8 mM Ca2+, n= 20 and 37 cells from 3 and 4 hearts, respectively; 5 mM Ca2+,
n= 20 cells from 3 hearts per group). Normalized peak amplitudes (e), decay time constants (obtained by ﬁtting to the decline phase) (f), and times to
peak (g) of Ca2+ transients. h Estimation of sarcoplasmic reticulum (SR) Ca2+ content (n= 15 and 10 cells from 3 and 2 hearts, respectively). #P < 0.05
between indicated groups based on Student’s t-tests.
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remodeling32,33. Fktn-deﬁcient myocytes showed abnormal
accumulation of PI4P (Fig. 5c) and surprisingly, fragmentation
of the Golgi apparatus under basal conditions, as revealed by
staining with the cis-Golgi marker protein GM130 (Fig. 5d).
These phenotypes may be indicative of PKD hyperactivation,
which subsequently impairs the MEF2-HDAC axis following
hypertrophic stimulation. Furthermore, PKD hyperactivation also
may be associated with Golgi fragmentation. Treatment of HEK
cells with the marine sponge metabolite ilimaquinone (a PKD
activator) induced the vesiculation of the Golgi, as observed via
GM130 staining (Fig. 5e, top middle). Alternatively, Fktn
elimination per se may affect Golgi structure. Remarkably, we
found that untreated FKTN-deﬁcient HEK cells showed an
elongated pattern of GM130 staining, suggesting that FKTN is
involved in maintaining the structure of the Golgi apparatus
(Fig. 5e, bottom left). In support of this notion, treatment with
ilimaquinone or the PKD inhibitor CID755673 did not result in
further disruption (Fig. 5e, bottom panels). In HAP cells, the
structure of the Golgi apparatus was changed in an FKTN-
dependent manner (Fig. 5f). These observations suggest the
possibility that FKTN contributes to the maintenance of the Golgi
architecture in these cells.
Acute elimination of Fktn results in severe cardiac dysfunction.
Although FKTN protein is likely involved in the maintenance of
myocytes, we did not observe structural and functional defects in
cardiomyocytes from young-adult mice. To examine the direct
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effect of Fktn elimination in young-adult mice, we generated
temporally controlled cardiomyocyte-speciﬁc Fktn-deﬁcient
[αMHC-MerCreMer (MCM)-Fktn-cKO] mice (Supplementary
Fig. 6). The treatment of 10-week-old αMHC-MCM-Fktn-cKO
(Fktnﬂox/ﬂox; αMHC-MCM+/−) mice for 4 d with tamoxifen-
induced chamber dilation and severe cardiac dysfunction (Fig. 6a,
b). Surprisingly, ~50% of these mice died within 1 week after
initiating tamoxifen treatments (Fig. 6c), suggesting an indis-
pensable role for FKTN in the working heart. Fktnﬂox/+; αMHC-
MCM+/− (hetero) mice showed no abnormalities in overall car-
diac structure and function or mortality rate after tamoxifen
treatment (Supplementary Fig. 7). As previously mentioned
(Fig. 1a), the glycosylation of α-DG (as detected with the IIH6
antibody) increases with age, such that levels are barely detectable
in hearts from 10-week-old mice. The hearts of tamoxifen-treated
αMHC-MCM-Fktn-cKO mice showed normal DGC protein
localization and levels of glycosylated α-DG (Supplementary
Fig. 8); this suggests that cardiac dysfunction at this stage (4 d
after tamoxifen injection) is independent of α-DG glycosylation
and DGC proteins in the sarcolemma. Cardiomyocytes isolated
from tamoxifen-treated αMHC-MCM-Fktn-cKO mice had
severely impaired contractility and Ca2+ handling during E–C
coupling with reduced amplitudes and delayed times to peak of
electrically evoked Ca2+ transients compared with those from
vehicle-treated controls (Fig. 6d–h).
Subcellular changes in αMHC-MCM-Fktn-cKO cardiomyo-
cytes. We next investigated how Fktn elimination affects con-
tractility and Ca2+ handling during E–C coupling, particularly via
the structure of T-tubules and myoﬁlaments and expression of
Ca2+ regulatory proteins. We analyzed the T-tubule structure and
found it was severely disordered in Fktn-deﬁcient cardiomyocytes
(Fig. 7a). The myocardia of tamoxifen-treated αMHC-MCM-
Fktn-cKO mice also showed subdivided subcellular myoﬁlaments
and disorganized Z-line structures (Fig. 7b, black arrowheads).
Thus, Fktn elimination directly leads to structural and functional
cardiomyocyte defects, especially of the T-tubules that form the
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key structure of E–C coupling, independent of α-DG glycosyla-
tion. Despite the severe structural disorganization of T-tubules,
the expression of Ca2+ regulatory proteins, including NCX1 and
LTCC, was not altered (Fig. 7c, d and Supplementary Fig. 9).
To investigate the mechanism of T-tubule disorganization in
Fktn-deﬁcient cardiomyocytes, we analyzed the expression levels
of junctophilin-2 (JP2) (Fig. 7c, e), a protein that bridges T-tubules
and SR membranes34,35. It is well known that misregulation of JP2
can be mediated via microtubules (MTs) and contributes to T-
tubule maintenance and Ca2+ mishandling in failing myo-
cytes34,35; therefore, we also analyzed the expression of α-tubulin,
a component of MTs, in hearts from tamoxifen-treated αMHC-
MCM-Fktn-cKO mice (Fig. 7c, f). JP2 expression was clearly
reduced in the hearts of tamoxifen-treated αMHC-MCM-Fktn-
cKO mice (Fig. 7c, e), whereas α-tubulin expression was
signiﬁcantly increased (Fig. 7c, f). Moreover, the distribution of
JP2 was altered in tamoxifen-treated αMHC-MCM-Fktn-cKO
cardiomyocytes (Fig. 7g). Therefore, we hypothesized that MT
densiﬁcation-mediated JP2 redistribution may be associated with
the cardiomyocyte contractile defects via T-tubule remodeling in
tamoxifen-treated αMHC-MCM-Fktn-cKO mice.
The effects of MT depolymerization in αMHC-MCM-Fktn-cKO
myocytes. Because MT densiﬁcation can impede myocyte
shortening35–38, we examined whether treatment with 10 μM
colchicine, which inhibits MT polymerization, for 1 h resolved
contractile dysfunction in tamoxifen-treated αMHC-MCM-Fktn-
cKO cardiomyocytes. In control cardiomyocytes, α-tubulin
immunostaining revealed a regulated meshwork pattern of MTs
(Fig. 8a, top left), with some polymerized MTs perpendicular to
the muscle ﬁber (Fig. 8a, top left inset). The meshwork pattern of
MTs was lost after treatment with 10 μM colchicine (Fig. 8a,
middle left), whereas cardiomyocyte shortening was not affected
in vehicle-treated control myocytes (Fig. 8b). In tamoxifen-
treated αMHC-MCM-Fktn-cKO cardiomyocytes, we observed an
accumulation of MTs in parallel with the muscle ﬁber (Fig. 8a,
top right and inset), and shortening was impaired compared with
that in the vehicle control (Fig. 8b). Notably, colchicine treatment
reduced this accumulation of MTs and reversed the impaired
shortening in tamoxifen-treated αMHC-MCM-Fktn-cKO cardi-
omyocytes (Fig. 8a, bottom right; Fig. 8b). Golgi elements in
muscles are major sites for the nucleation of MTs39, and the
irregular accumulation of MTs, due to the disorganization and
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abnormal distribution of the Golgi apparatus, has recently been
implicated in the progression of heart failure34,35,40,41. Interest-
ingly, treatment with 10 μM colchicine disrupted the Golgi
apparatus (Fig. 8a, middle left), consistent with the idea that MTs
are crucial for proper localization of the Golgi in a wide range of
cells34. Remarkably, this fragmentation of the Golgi did not affect
cardiomyocyte shortening (Fig. 8b). Instead, the activation of
PKD with ilimaquinone resulted in vesiculation in the Golgi
apparatus, an accumulation of MTs (Fig. 8a, bottom left and
inset), and contractile dysfunction (Fig. 8b) in control cardio-
myocytes. In tamoxifen-treated αMHC-MCM-Fktn-cKO cardio-
myocytes, we also observed abnormal fragmentation of the Golgi
apparatus (Fig. 8a, top right, white arrowheads). These results
suggest that contractile dysfunction in FKTN-deﬁcient cardio-
myocytes is caused by MT densiﬁcation that may be associated
with Golgi abnormalities. In tamoxifen-treated αMHC-MCM-
Fktn-cKO hearts, the level of PKD phosphorylation was sig-
niﬁcantly higher than that in control hearts (Fig. 8c), suggesting
that FKTN impacts the integrity of the Golgi structure by reg-
ulating PKD signaling pathways. We also observed abnormal
distribution of the Golgi apparatus and the accumulation of MT
structures in MCK-Fktn-cKO mice in late adulthood (Supple-
mentary Fig. 10). Control myocytes from 10-month-old mice also
exhibit the accumulation of MT structures. While membrane
abnormalities were observed in cardiomyocytes isolated from 10-
month-old MCK-Fktn-cKO mice (Supplementary Fig. 10), the
severity was less than that observed in tamoxifen-treated αMHC-
MCM-Fktn-cKO hearts (Fig. 7a). Additionally, phosphorylation
of PKD was decreased in cardiomyocytes isolated from MCK-
Fktn-cKO mice 48 weeks after birth (Supplementary Fig. 11). On
the other hand, reduction of FKTN protein immediately led to the
abnormal fragmentation of the Golgi apparatus, MT densiﬁca-
tion, and PKD phosphorylation in tamoxifen-treated αMHC-
MCM-Fktn-cKO hearts (Fig. 8). These data suggest that FKTN
plays a crucial role in the maintenance of the Golgi-derived MT
network and PKD signaling.
To elucidate how colchicine improves myocyte contractility, we
assessed Ca2+ handling during E–C coupling in cardiomyocytes
isolated from tamoxifen-treated αMHC-MCM-Fktn-cKO hearts.
We found that colchicine treatment enhanced intracellular Ca2+
handling in tamoxifen-treated αMHC-MCM-Fktn-cKO myocytes
(Fig. 8d). This was associated with improved myocyte contractile
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efﬁciency as evidenced by the ratio of cell shortening to the
amplitude of Ca2+ increase during E–C coupling (Fig. 8e). Thus,
colchicine appears to improve myocyte contractility by improving
Ca2+ handling and reducing the stiffness of cardiomyocytes
(Fig. 8e).
Finally, we showed that colchicine ameliorated the heart failure
phenotype in tamoxifen-treated αMHC-MCM-Fktn-cKO mice.
Chamber dilation, ﬁbrosis, cardiac dysfunction, and survival rates
after 10 d of tamoxifen treatment were all improved by colchicine
administration (Fig. 9a–e). These observations suggest acute
elimination of Fktn contributes to myocyte contractile dysfunc-
tion as a result of MT densiﬁcation.
Mechanistic analysis for Golgi pathology in Fktn-deﬁcient hearts.
To elucidate how FKTN regulates Golgi structure and function
and thus leads to MT accumulation, we performed microarray
analysis of tamoxifen-treated ﬂoxed or αMHC-MCM-Fktn-cKO
hearts and investigated the putative pathway and biological
processes induced by deletion of Fktn. A total of 31,762 probe sets
obtained from an Agilent gene expression microarray platform
(SurePrint G3 Mouse Gene Expression 8 × 60 K) were tested for
differential expression. We found that 7408 genes were differ-
entially expressed on the basis of a criterion of at least a twofold
change and adjusted value of P < 0.05 when cKO was compared
with ﬂoxed-control; 4536 transcripts were downregulated and
2872 transcripts were upregulated in αMHC-MCM-Fktn-cKO
hearts (Table I in the online-only Data Supplement). Hierarchical
clustering revealed a high level of homogeneity within and a clear
separation between groups (Supplementary Fig. 12). A heatmap
displaying expression levels of 1,611 differentially expressed Golgi
apparatus-related genes annotated from a global cross-database
NCBI search showed excellent consistency of changes within
groups (Fig. 10a). Thus, the elimination of Fktn impacts the
expression proﬁle of Golgi-related genes.
Integrity of the Golgi apparatus requires the MT network42. We
focused on genes known to be relevant to nucleation and dynamics
of Golgi-derived MTs: Tpx2 (coding for a targeting protein of
Xklp2), Rab3a (coding for RAS oncogene family member 3a),
Pde4dip (coding for myomegalin), Pcnt (coding for pericentrin),
and Clasp1 (coding for CLIP-associating protein 1)42. The positions
of these genes in the volcano plot are depicted in Fig. 10b. Although
the MT nucleation factor encoded by Tpx2 was increased, the
anchoring proteins of the γ-tubulin ring complex (γ-TuRC) of the
cis-Golgi encoded by Pde4dip and Pcnt were reduced in cKO hearts.
The MT-stabilizing protein encoded by Clasp1 was also reduced in
cKO hearts. These observations suggest that Fktn elimination leads
to a decline in the stability and dynamics of the Golgi-derived
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MT network. In addition, the downregulation of Rab3a suggests a
decline in post-Golgi secretory trafﬁcking43 in cKO hearts.
Pathway enrichment analysis of the downregulated genes in
cKO hearts (FDR < 0.001, Log2FC <−1.5) revealed enrichment of
pathways involved in cardiac physiology (i.e., muscle contraction
and cardiac conduction; Supplementary Fig. 12). On the other
hand, upregulated genes in cKO hearts (FDR < 0.001, Log2FC <
−1.5) revealed enrichment of pathways involved in the cell cycle,
Rho GTPase signaling, extracellular matrix organization or
degradation, integrin cell surface interaction, and extracellular
matrix proteoglycan as analyzed by ReactomePA (https://
reactome.org/; Fig. 10c). These pathways were inﬂuenced by the
stability and dynamics of Golgi-derived MT, protein synthesis at
the Golgi apparatus, and membrane transport via MT in cells.
Thus, these observations emphasize the possibility that disin-
tegration of the Golgi apparatus and Golgi-derived MT network is
one etiology of muscular dystrophy-associated heart failure in
Fktn-deﬁcient mice.
Kyoto Encyclopedia of Gene and Genomes (KEGG) functional
network analysis of the 7408 genes showed large ﬂuctuations with
high signiﬁcance for Parkinson’s, Huntington’s, and Alzheimer’s
diseases (Fig. 10d). Structural and functional alteration of the
Golgi apparatus is recognized as a constant pathological hallmark
of neurodegenerative disease, including Parkinson’s, Hunting-
ton’s, and Alzheimer’s diseases43. A pathway related to
hypertrophic cardiomyopathy and dilated cardiomyopathy was
also prominent. These results suggest that the pathological
mechanism of cardiac dysfunction induced by Fktn elimination
partly overlaps with that of neurodegenerative disease.
To investigate the cause of the Golgi pathology observed in
Fktn elimination, we examined localization of the α-DG protein
using antibody against the core region of α-DG (core α-DG) in
cultured neonatal cardiomyocytes isolated from MCK-Fktn-cKO
hearts (Fig. 10e). In control myocytes, core α-DG co-localized
with the post-Golgi marker Rab3a beneath the membrane
(Fig. 10e, upper panels). On the other hand, although core
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α-DG also co-localized with Rab3a in cKO myocytes, its signal
accumulated intracellularly on the vesicle structure (Fig. 10e,
lower panels). Next, we examined whether accumulation of core
α-DG is a critical factor in disorganization of the Golgi apparatus
(Fig. 10f). We observed faint signals of anti-core α-DG antibody
beneath the membrane in HEK cells (Fig. 10f, upper panels). On
the other hand, FKTN-KO HEK cells showed internally
accumulated core α-DG, which mainly co-localized with Rab3a,
and fragmentation of the Golgi apparatus (Fig. 10f, middle
panels). Forced expression of full-length DG induced accumula-
tion of core α-DG in the post-Golgi area, which co-localized with
Rab3a (Fig. 10f, left lower panels). However, we did not observe
fragmentation of the Golgi apparatus by GM130 labeling (Fig. 10f,
right lower panels). These observations suggest that accumulation
of core α-DG does not trigger the Golgi pathology observed in
Fktn-deﬁcient cells and thus that FKTN may be critical for the
maintenance of Golgi structure and function.
Discussion
As DG glycosylation and the DGC play essential roles in the
connection between the basement membrane and sarcolemma in
skeletal muscle23,44, the loss of membrane integrity has been
thought to be a cause of muscle damage in cardiac tissues45. In
support of this hypothesis, it was shown that DG limits cardiac
myocyte membrane damage46. In addition, our present study
demonstrates, for the ﬁrst time, the cellular and molecular
pathomechanisms of heart failure associated with α-DGpathy.
Studies of skeletal muscle-speciﬁc Fktn-cKO mice indicate that
the loss of functional α-DG protein likely contributes to the
pathogenesis of muscular dystrophy23,44. Surprisingly, our study
shows a lack of cardiac dysfunction in young-adult MCK-Fktn-
cKO mice despite the marked reduction in DGC proteins in the
cardiac sarcolemma, suggesting that membrane fragility is not the
sole etiology of cardiac dysfunction. Cardiac dysfunction with
impaired myocyte shortening in old age (Figs. 1 and 2) or vul-
nerability to hemodynamic stress at a young age (Fig. 3) in MCK
promoter-driven cKO hearts suggests that the FKTN protein is
critical for maintaining cardiac structure and function under
conditions of aging and hemodynamic stress. Therefore, MCK
promoter-driven cKO hearts may have an unknown compensa-
tory mechanism that prevents mice from manifesting any obvious
phenotypes of FKTN deﬁciency during the young-adult age under
normal physiological conditions. Therefore, it is possible that the
acute Fktn deﬁciency results in severe cardiac dysfunction and
reduced survival in the young mice. Notably, DGC localization
was not affected in these young mice, suggesting that reduced α-
DG glycosylation and DGC expression may not be the sole rea-
sons for cardiac dysfunction.
A main ﬁnding is that FKTN is crucial for maintaining con-
tractile function and Ca2+ handling during E–C coupling in
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colchicine treatment, and sample collection. Blue letters show the dose of colchicine. b Cardiac morphology (scale bar, 5 mm). c Masson’s trichrome
staining of the left ventricle (scale bar, 50 μm). Cardiac function in tamoxifen-treated αMHC-MCM-Fktn-cKO hearts treated with colchicine (d) and
survival percentages (e) (n= 10 per group). *P < 0.05 vs. tamoxifen-treated αMHC-MCM-Fktn-cKO mice based on Student’s t-tests.
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individual cardiomyocytes. By contrast, previous studies of
dystrophin-deﬁcient mdx mice found changes in Ca2+ signaling
with only slightly elevated resting intracellular concentrations and
potentially arrhythmogenic E–C coupling in ventricular myo-
cytes47,48. Homeostasis in young-adult Fktn-deﬁcient mice may
have been achieved by reduced Ca2+ inﬂux through LTCC and
increased efﬂux by NCX1 or SERCA (Supplementary Fig. 13),
proteins that play important roles in Ca2+ homeostasis and Ca2+
handling during E–C coupling27,49,50. These alterations indicate
that reserved capacity in responses to cardiomyocytes stress was
impaired without causing signiﬁcant cardiac dysfunction.
Chronic isoproterenol treatment in these mice downregulated
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Akt and upregulated CamKII, suggesting altered Ca2+-dependent
signaling. Thus, the inability to precisely regulate intracellular Ca2
+ after Fktn elimination likely impacted cell survival in the long
run. Indeed, we also observed an upregulation of the hypertrophic
mediator calcineurin51 and a downregulation of its endogenous
inhibitor MCIP52, along with strong induction of the hyper-
trophic marker ANP, in MCK-Fktn-cKO mice at 16 weeks of age
(Supplementary Fig. 13). Thus, at this age, hypertrophic remo-
deling, mediated by Ca2+-calcineurin signaling, is already
underway before abnormalities in morphology and contractility
emerge. In our study, Fktn-deﬁcient cardiomyocytes showed
hyperphosphorylation and altered localization of HDAC9, which
is a direct transcriptional target of MEF2 and acts as signal-
responsive repressor of cardiac hypertrophy31. HDAC9-knockout
mice are ultrasensitive to hypertrophic stimuli and spontaneously
develop cardiac hypertrophy with advanced age31. Thus, HDAC9
alterations can be associated with the vulnerability to stress in
Fktn-deﬁcient myocytes. The constitutive phosphorylation of
PKD, which transduces signals for diacylglycerol biogenesis53,
and hyperphosphorylation of HDAC9 under basal conditions in
the hearts of Fktn-deﬁcient mice suggest there may be excessive
transcriptional activation in response to stress.
Another key ﬁnding is that FKTN is essential for maintaining
the Golgi-derived MT network in cardiomyocytes. Constitutively
phosphorylated PKD in myocytes from young MCK-Fktn-cKO
mice or tamoxifen-treated αMHC-MCM-Fktn-cKO myocytes
may remain associated with the cytoplasmic surfaces of Golgi
membranes and regulate the ﬁssion of vesicles that carry protein
and lipid cargo to the plasma membrane54. We also observed the
vesiculation of Golgi and accumulation of MT in the myocytes
from old MCK-Fktn-cKO mice (Supplementary Fig. 10), sup-
porting the notion that FKTN is involved in the maintenance of
the Golgi-MT network. Alternatively, PKD phosphorylation in
myocytes from old MCK-Fktn-cKO mice was lower than that in
control myocytes (Supplementary Fig. 11). This contradiction
may be explained by differences in timing of Fktn deletion, dis-
ease progression course (period), and hemodynamic stress con-
ditions, thus reﬂecting pathogenesis and/or pathological
consequences. Nonetheless, our data show that FKTN protein
plays a role in the maintenance of Golgi-MT network in cardi-
omyocytes. Considering the results that old MCK-Fktn-cKO mice
showed very mild pathology compared to isoproterenol-treated
young MCK-Fktn-cKO mice or tamoxifen-treated αMHC-MCM-
Fktn-cKO mice, our data also suggest the presence of a com-
pensatory mechanism during long-term progression in the pre-
sence of Fktn deﬁciency.
The altered distribution of GM130 in FKTN-deﬁcient HAP
and HEK cells indicates that the Golgi morphology was also
altered independently of PKD activity (Fig. 5e, f). Impairment of
glycosylation by Fktn deﬁciency may accelerate fragmentation of
the Golgi apparatus by enhancing the budding of vesicles from
the Golgi membrane or disrupting protein trafﬁcking. We
observed the accumulation of core α-DG in the post-Golgi area
and fragmentation of the Golgi apparatus in Fktn-deﬁcient
cardiomyocytes and HEK cells (Fig. 10e, f). HEK cells expressing
full-length α-DG also showed accumulation of core α-DG in the
post-Golgi area (Fig. 10f). However, we did not observe abnormal
fragmentation of the Golgi apparatus in cells, suggesting a pivotal
role of FKTN in the maintenance of Golgi integrity (Fig. 10f).
FKTN is targeted to the medial Golgi apparatus through its N-
termini and transmembrane domain55. Therefore, the lack of
FKTN per se might affect the integrity of the Golgi ribbon.
Alternatively, FKTN also forms a complex with other Golgi-
resident glycosyltransferases56,57, and thus, the lack of FKTN may
change cellular glycosylation, affecting Golgi structure and
function. The results of our microarray analysis also suggest the
impact of FKTN on expression of Golgi-related genes. Elimina-
tion of Fktn led to the downregulation of genes encoding the
anchoring protein of γ-TuRC at cis-Golgi and MT-stabilizing
protein (Fig. 10b). Golgi-derived MT networks serve important
roles in post-Golgi trafﬁcking, maintenance of Golgi integrity, cell
polarity, and cellular function42. The disruption of MT dynamics
in Fktn-deﬁcient myocytes may impact Golgi vesiculation, with
the accumulation and densiﬁcation of MTs affecting both the
central cellular localization of Golgi and ER–Golgi–plasma
membrane trafﬁcking, which indirectly impacts the size and
morphology of the Golgi58. Recent studies show that disintegra-
tion of Golgi structure and function is one of the main causes of
Alzheimer’s disease42. In this disease, precipitation of hyper-
phosphorylated tau protein is also related to Golgi structure and
function42. Remarkably, KEGG analysis suggested that heart
failure induced by acute Fktn elimination has a common etiology
with neuromuscular disease (Fig. 10d). Our results further suggest
a mechanistic connection between the Golgi apparatus and
myocyte T-tubule organization, which is crucial for Ca2+
homeostasis in cardiomyocytes. Further investigations will clarify
the FKTN-dependent maintenance of Golgi-derived MT
networks.
Cardiomyocytes isolated from acute Fktn deﬁciency in young
mice had dramatically disrupted T-tubule membranes and MT
densiﬁcation, as seen in failing hearts of human patients and
animal models35,59,60. Studies show that MT-mediated defects in
JP2 trafﬁcking contribute to myocyte T-tubule remodeling in
heart failure34,38. Here, we show that Fktn elimination also led to
a reduction and redistribution of JP2. Thus, disorganization of the
T-tubule membrane in Fktn-deﬁcient mice might be caused by
MT-mediated defects in JP2 trafﬁcking. These changes con-
tributed to reduced myocyte contractility and cardiac dysfunc-
tion, which were ameliorated by colchicine treatment. These data
suggest that the accumulation of MTs after Fktn elimination is a
major contributor to myocyte dysfunction and that an effective
therapeutic strategy for heart failure involves MT depolymeriza-
tion. MT densiﬁcation increases the stiffness of cells, thereby
mechanically impeding sarcomere motion40, and alters T-tubules,
which are important for E–C coupling34. We show that treatment
with colchicine not only restored myocyte shortening, Ca2+
handling during E–C coupling, and contractile efﬁciency but also
ameliorated severe cardiac dysfunction and improved the survival
Fig. 10 Fktn elimination impacts Golgi-related genes and structure. a Microarray analysis using ﬂoxed and αMHC-MCM-Fktn-cKO (Fktnﬂox/ﬂox;
αMHC-MCM+/−) hearts treated with tamoxifen for 4 d. Heat map displaying hierarchical clustering and expression levels of differentially expressed
Golgi apparatus-related genes. b Volcano plot of upregulated or downregulated genes in tamoxifen-treated αMHC-MCM-Fktn-cKO (Fktnﬂox/ﬂox;
αMHC-MCM+/−) hearts. Dots indicating Pde4dip, Pcnt, and Clasp are overlapping. c Gene set enrichment analysis revealing enriched pathways and
processes in tamoxifen-treated αMHC-MCM-Fktn-cKO hearts. d Signiﬁcantly enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) categories
show differentially expressed gene pathways in tamoxifen-treated αMHC-MCM-Fktn-cKO hearts. e Representative immunoﬂuorescence images of
neonatal cardiomyocytes cultured with FCS (Core DG, green; Rab3a, red; DAPI, blue). Scale bar, 50 μm. f Representative immunoﬂuorescence images of
HEK, FKTN-KO HEK, and HEK expressing full-length DG (Core DG, green; Rab3a, red; DAPI, blue (left panels); Core DG, green; GM130, red; DAPI, blue
(right panels)). Scale bar, 50 μm.
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of mice with FKTN deﬁciency. One question is whether colchi-
cine treatment can be applied to other forms of muscular
dystrophy-associated cardiomyopathies. Answering this question
requires a system that can tightly control the timing of elim-
inating the expression of the responsible gene, as we did in this
study. However, a previous report suggested that colchicine
treatment improves Ca2+ handling in mdx mice38, a model for
DMD; although, the exact mechanism remains to be elucidated.
Importantly, as colchicine is already an FDA-approved drug for
the treatment of familial Mediterranean fever and acute gout
ﬂares, our ﬁndings suggest that this drug may also be useful for
treating muscular dystrophy-associated heart failure.
Several studies have raised concerns that tamoxifen treatment
may adversely inﬂuence cardiac function in adult MCM
mice61,62. DNA damage response occurs in these hearts, resulting
in cardiomyocyte apoptosis, cardiac ﬁbrosis, and cardiac dys-
function61. Therefore, Koitabashi et al.63 recommended a reduced
tamoxifen dosage of <20 mg/kg of body weight per day for use in
αMHC-MCM+/− mice (an approximate total dose of 80 mg/kg).
In this study, we administered tamoxifen by intraperitoneal (i.p.)
injection consecutively for 4 d at a dosage of 8 mg/kg of body
weight in 10-week-old Fktnﬂox/ﬂox;MCM+/–, Fktnﬂox/+;MCM+/–,
and Fktnﬂox/ﬂox;MCM–/– mice. This dose (8 mg/kg per d,
approximate total dose of 32 mg/kg) was sufﬁcient for reducing
FKTN protein expression and Fktn transcription (Supplementary
Fig. 6e and Fig. 10b). In our microarray analysis, we were unable
to detect any alterations in the signaling pathways involved in
DNA damage response in Fktnﬂox/ﬂox; αMHC-MCM+/− hearts
treated with tamoxifen for 4 d (Fig. 10). In addition, tamoxifen
treatment had no effect on the overall cardiac structure and
function of Fktnﬂox/+;αMHC-MCM+/− (hetero) mice (Supple-
mentary Fig. 7). Together, our results show that the heart-failure
phenotype seen in tamoxifen-treated αMHC-MCM-Fktn-cKO
(Fktnﬂox/ﬂox; αMHC-MCM+/−) mice is not due to adverse effects
of tamoxifen or excessive MCM expression. After 4 d of tamox-
ifen treatments, Fktn mRNA levels were reduced by about 80%
in the hearts of αMHC-MCM-Fktn-cKO (Fktnﬂox/ﬂox;αMHC-
MCM+/−) mice (Supplementary Fig. 7c). In addition, FKTN
protein expression was reduced by 80–90% in αMHC-MCM-
Fktn-cKO (Fktnﬂox/ﬂox;αMHC-MCM+/−) mice after 4 d of
tamoxifen treatment or 6 d after the onset of tamoxifen treatment
compared with vehicle control hearts (Supplementary Fig. 6e).
These data also suggest that the half-life of FKTN protein is <4 d.
Thus, FKTN mRNA and/or FKTN protein likely have a fast
turnover rate. Altogether, our data strongly suggest that acute
reduction of FKTN protein expression results in severe cardiac
dysfunction in tamoxifen-treated Fktnﬂox/ﬂox; αMHC-MCM+/−
mice. Thus, FKTN protein is crucial for the maintenance of
cardiac structure and function in mice.
Methods
Animals. All the mouse experiments have been done according to the all relevant
ethical regulations. Mice were housed in a facility accredited by the Japan Act on the
Welfare and Management of Animals (No. 105). All animal studies were approved
by the Institutional Animal Care and Use Committee of Okayama University
(Okayama, Japan), and conformed to the Japan Act on the Welfare and Manage-
ment of Animals (No. 105). Littermates were used in this study to randomize
genetic variation. Mice carrying a Fktnﬂox/ﬂox allele for conditional deletion of FKTN
exon 2 were generated by homologous recombination in mouse C57BL/6 ES cells23.
To produce Fktnﬂox/ﬂox;MCK-Cre+/– (MCK-Fktn-cKO) mice, Fktnﬂox/ﬂox mice
were mated with transgenic mice expressing Cre recombinases under the control of
the MCK promoter (B6.FVB(129S4)-Tg(Ckmm-cre)5Khn/J; The Jackson Labora-
tory, Stock No. 006475), and the offspring were back-crossed with Fktnﬂox/ﬂox mice
(C57BL/6 background) over 25 generations. Transgenic mice expressing
tamoxifen-inducible cardiomyocyte-speciﬁc Cre recombinase, αMHC-MCM+/−
(FVB/N background; The Jackson Laboratory, Stock No. 005650), were back-
crossed with C57BL/6 mice over 20 generations. To delete the ﬂoxed alleles in a
tamoxifen-inducible cardiomyocyte-speciﬁc manner, Fktnﬂox/ﬂox mice were
mated with αMHC-MCM+/− mice from an obtained colony, and the offspring
were back-crossed with Fktnﬂox/ﬂox mice (C57BL/6 background) over 20 genera-
tions. As a result, we obtained C57BL/6-congenic Fktnﬂox/ﬂox;αMHC-MCM+/–
mice (αMHC-MCM-Fktn-cKO). We used Fktnﬂox/ﬂox littermates mainly as age-
matched controls in this study. Germline transmission of Fktn conditional null
alleles was conﬁrmed by Southern blotting and PCR genotyping using the primer
pair, Fukutin-F, 5′-GTCAAATAGCATAATTACGGGACAG-3′ and Fukutin-R,
5′-CAAGTATGGCAGTACACATTTATCG-3′, yielding products of 778 bp (wild
type) and 870 bp (null allele). Cre transgene was conﬁrmed by PCR using primer
pair, cre-newF, 5′-CCATCTGCCACCAGCCAG–3′ and cre-newR, 5′-TCGCCA
TCTTCCAGCAGG-3′. To induce Cre-mediated recombination, 8 mg/kg tamox-
ifen or its vehicle (peanut oil) as a control was administered by i.p. injection to
Fktnﬂox/ﬂox;MCM+/–, Fktnﬂox/+;MCM+/–, and Fktnﬂox/ﬂox;MCM–/– mice once
daily for 4 consecutive days. Colchicine or its vehicle (saline) was administered by i.
p. injection from 2 d after the start of tamoxifen. The injection began with 0.4 mg/
kg and progressed to 1 mg/kg (0.4 mg/kg, 0.6 mg/kg, 0.8 mg/kg, and 1 mg/kg) to
allow the mice to adjust to the drug. Then, 1 mg/kg colchicine administration
continued until 10 d after the start of tamoxifen treatment. For treatments with
phenylephrine and isoproterenol, micro-osmotic pumps (Azlet model 1002) were
inserted subcutaneously, delivering 80 mg/kg/d phenylephrine or 20 mg/kg/d iso-
proterenol for 2 weeks. Control animals were treated with saline.
Thoracic aortic constriction surgery. Left ventricular pressure overload was
induced by thoracic aortic constriction. The 10-week-old mice (weighing 20–22 g)
were anesthetized by i.p. injections of a mixture of ketamine (100 mg/kg) and
xylazine (5 mg/kg). After orotracheal intubation, cannulae were connected to a
volume-cycled ventilator (SN-480-7; Shimano, Japan) with room air at a tidal
volume of 0.2 ml and a respiratory rate of 110 breaths per minute. The chest
cavities were entered through small incisions to the second intercostal space, and
the transverse aortas were constricted with 7-0 nylon strings by ligating with a
blunted 27-gauge needle, which was later removed.
Neonatal cardiomyocyte culture. Primary cardiomyocyte cultures were prepared
from ventricles of 1-d-old mice by very gentle trypsinization at room temperature
using a modiﬁed method for rat neonatal hearts46. Brieﬂy, hearts were rapidly
removed from neonatal MCK-Fktn-cKO or control (ﬂoxed) mice anesthetized with
an overdose of pentobarbital (30 mg/kg, i.p.). The ventricles were excised, cut into
several pieces, and washed three times with 10 ml ice-cold PBS for 1 min by gentle
shaking. The tissue pieces were digested three times with 0.06% trypsin in DMEM
(8 ml) for 8 min at 37 °C by gentle agitation. The cells were resuspended in DMEM
with 10% FCS to stop trypsinization and centrifuged at 1400 × g for 3 min. The cell
pellets were resuspended in fresh DMEM containing 10% FCS, plated on collagen-
coated 24-well dishes at a density of 4 × 104 cells per well, and maintained in
DMEM containing 10% FCS. After 24 h, the cells were divided into three groups
and then maintained for up to 72 h in DMEM alone or DMEM with 10% FCS or
with 10 μM phenylephrine. The formation of myocytes clusters and spontaneous
synchronized beating were conﬁrmed by observation under an inverted microscope
(CKX41; Olympus). Cellular viability was investigated at 48 h of culture by using a
The LIVE/DEA Fixable Green Dead Cell Stain Kit (Invitrogen). Cells viability were
validated on three independent experiments for cell type.
Isolation of adult mouse ventricular myocytes. Ventricular myocytes were
obtained from 10-month-old male MCK-Fknt-cKO, αMHC-MCM-Fknt-cKO, or
ﬂoxed-control mice. Hearts were rapidly removed from adult mice anesthetized
with an overdose of pentobarbital (300 mg/kg, i.p.) and Langendorff-perfused at a
constant hydrostatic pressure of 70 cm H2O at 37 °C using cell-isolation buffer
(CIB; 130 mM NaCl, 5.4 mM KCl, 0.5 mM MgCl2, 0.33 mM NaH2PO4, 22 mM
glucose, 50 nM/ml bovine insulin, and 25 HEPES-NaOH (pH 7.4)) supplemented
with 0.4 mM EGTA, which chelates calcium within the heart. Insulin was used
from a 1 U/ml stock solution in 0.1 mM HCl (pH 4.0). EGTA was from a 400 mM
stock in 1M NaOH (pH 7.8). The perfusate was then switched to the enzyme
solution (15 ml) of CIB supplemented with 0.3 mM CaCl2, 1 mg/ml collagenase,
0.06 mg/ml trypsin, and 0.06 mg/ml protease. Once the tissue had undergone
complete digestion, the ventricles were excised, cut into several pieces, and further
digested in fresh enzyme solution (15 ml) for 15–20 min at 37 °C until they were
mostly dissociated. The CaCl2 level in this enzyme solution was increased to 0.7
mM and supplemented with 2 mg/ml BSA. The cell suspension was centrifuged at
1400 × g for 3 min. The cell pellet (~0.1 ml) was resuspended in CIB supplemented
with 1.2 mM CaCl2 and 2 mg/ml BSA, then incubated at 37 °C for 10 min, cen-
trifuged (1400 × g for 3 min), and resuspended in 10 ml Tyrode’s solution (140 mM
NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.5 mM MgCl2, 0.33 mM NaH2PO4, 11 mM
glucose, and 5 mM HEPES-NaOH (pH 7.4)) supplemented with 2 mg/ml BSA.
Isolated cardiomyocytes were incubated at 37 °C in Tyrode’s solution containing
10 μM colchicine for 1 h to depolymerize MTs or 25 μM ilimaquinone for 15 min
to induce vesiculation of Golgi membranes.
Cell shortening and Ca2+ transients in isolated myocytes. Isolated cardio-
myocytes were loaded with 10 µM Indo-1 AM and electrically stimulated at 1 Hz
using a two-platinum electrode insert connected to a bipolar stimulator (SEN-3301;
Nihon Kohden) on the stage of an inverted microscope (IX71; Olympus) with a
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20× water immersion objective lens (UApo N340; Olympus). Calcium transients
were measured as the ratio of ﬂuorescence emitted at 405/480 nm, after excitation
at 340 nm, using a high-performance Evolve EMCCD camera (Photometrics).
Cardiomyocytes were maintained under continuous ﬂow in standard Tyrode’s
solution, exchanged using a microperfusion system. The experiments were recor-
ded and analyzed using MetaMorph software (version 7.7.1.0; Molecular Devices).
To estimate the effect of colchicine on cell contraction, we calculated the efﬁciency
of converting elevated Ca2+ levels to cell contraction by dividing the percentage of
cell shortening by the Ca2+ amplitude.
SR Ca2+ contents in adult cardiac myocytes. SR Ca2+ content was assessed by
rapid applying 10 mM caffeine and measuring the resulting Ca2+ transients in
isolated cardiomyocytes. Fura-2 acetoxymethyl ester (Fura-2)-loaded myocytes
were alternately excited at 340 and 380 nm using a Lambda DG-4 ultra-high-speed
wavelength switcher (Sutter Instrument) coupled to an inverted microscope IX71
(Olympus) with a UApo 20×/0.75 objective lens (Olympus). The Fura-2 ﬂuorescent
signal was recorded by ORCA-Flash 2.8 (Hamamatsu Photonics) and analyzed
using a ratiometric ﬂuorescence method with MetaFluor software (version 7.7.5.0;
Molecular Devices).
Generation of knockout cell line with CRISPR/Cas9. The CRISPR/Cas9 tar-
geting sequence for FKTN was GAGTAGAATCAATAAGAACG. The oligonu-
cleotides for this sequence were inserted into the Cas9 Smart nuclease all-in-one
vector (System Biosciences, Mountain View, CA) with an additional 8-base
sequence at the 5′ terminus. The vector was transfected into HEK293 (American
Type Culture Collection, Manassas, VA, USA; CRL-1573) or HAP1 cells (Haplo-
gen, Vienna, Austria; C631). IIH6-negative cells were sorted by ﬂuorescence-
activated cell sorting (MoFlo, Beckman Coulter, Brea, CA). HEK293 cells were
cultured in DMEM supplemented with 10% FCS and penicillin/streptomycin.
HAP1 cells were cultured in Iscove’s modiﬁed Dulbecco’s medium (Wako Pure
Chemical Industries) supplemented with 10% FCS and penicillin/streptomycin.
Each cell clone was veriﬁed for IIH6 reactivity by Western blot analysis and DNA
sequencing. The mutations in each clone were as follows: (HEK293 cell is a tri-
ploid) HEK FKTN1o-2 (27-bp deletion, 1-bp deletion, and 1-bp insertion in exon
2, causing frameshifts) and HAP FKTN5 (34-bp deletion in exon 2, causing a
frameshift).
Histology. Hearts were excised and immediately ﬁxed in buffered 4% paraf-
ormaldehyde, embedded in parafﬁn, and sectioned at a thickness of 4 µm.
Electron microscopy. Excised hearts were ﬁxed in 2% paraformaldehyde/2%
glutaraldehyde in PBS. The sections were examined under a JEM-1200 electron
microscope (Nihondensi, Co., Japan).
Antibodies. The following antibodies were used for immunostaining or
immunoblot analysis: anti-IIH6 (1:500 dilution, 05–593, Millipore); anti-β-DG
(1:1000 dilution, B-DG-CE, Novocastra); anti-dystrophin (1,1000 dilution, sc-
15376), anti-JP2 (1:500 dilution, sc-51313), anti-calcineurin (1:1000 dilution, sc-
9070), anti-CamKII (1:1000 dilution, sc-9035), and anti-phosphorylated CamKII
(1:1000 dilution, sc-12886) (Santa Cruz); anti-αSG (1:500 dilution, 20A6), anti-
βSG (1:500 dilution, 5B1), and anti-γSG (1:500 dilution, 2185) (Leica); anti-Akt
(1:1000 dilution, 9272), anti-phosphorylated Akt (1:1000 dilution, 4060), anti-
PKD (1:1000 dilution, 2052), anti-phosphorylated PKD (S916, S744) (1:1000
dilution, 2051 and 2054, respectively), anti-HDAC9 (1:1000 dilution, 7628), and
anti-MEF2 (1:1000 dilution, 5030) (Cell Signaling); anti-GAPDH (1:2000 dilu-
tion, ab9484), anti-MCIP (1:1000 dilution, ab25124), and anti-GM130 (1:500
dilution, ab52649) (Abcam); anti-phosphorylated HDAC9 (1:1000 dilution,
SAB4300269) and anti-α-tubulin (1:100 dilution, T5168) (Sigma); anti-PI4P
(1:500 dilution, Z-P004) (Echelon); anti-Na+/K+ ATPase (1:1000 dilution,
07–674), anti-SERCA (1:1000 dilution, MA3-910), and anti-RyR (1:1000 dilu-
tion, MA3-916) (Thermo); anti-ANP (1;500 dilution, H005-24, Phoenix); anti-
Cav3 (1:1000 dilution, 610420, BD Pharmingen); and anti-LTCC (1:1000 dilu-
tion, AC-003, Alomone). The anti-NCX1 antibody was generated in our
laboratory. Anti-core α-DG is previously reported64.
Immunocytochemistry. Frozen heart sections (5 μm), embedded in OCT com-
pound (Tissue-Tek), were permeabilized with 0.1% Triton X-100 and incubated
with primary antibodies. Mouse On Mouse (M.O.M.) Blocking Reagent (Vector
Laboratories) was used to block endogenous mouse antibody in the tissue sections.
Cells were examined using a confocal microscope (Fluoview FV1000; Olympus)
mounted on an Olympus IX81 epiﬂuorescence microscope with a UPlanSApo 60×/
1.35 oil immersion objective lens (Olympus).
Immunoblotting. Mice hearts were homogenized using a Hiscotron homogenizer
(NITI-ON) in lysis buffer containing 20mM HEPES (pH 7.4), 150mM NaCl, 1%
sodium deoxycholate, 1% SDS, 2 µg/ml leupeptin, 1 µg/ml aprotinin, 200 µM phe-
nylmethylsulfonyl ﬂuoride, and 200 µM benzamidine hydrochloride. The lysates were
centrifuged at 100,000 × g for 20min and the supernatants were used for immunoblot
analysis. DG from solubilized myocardium was enriched with wheat germ agglutinin-
agarose beads (Vector Laboratories). To detect the expression of FKTN protein,
cardiac muscles were solubilized with 1% Triton X-100 in TBS. The solubilized
samples were assayed for total protein concentration and then 4mg of proteins were
subjected to FKTN antibody-conjugated beads to enrich FKTN proteins as previously
reported65. The bound materials were eluted with 0.1M glycine-HCl (pH 2.5) and
then analyzed by Western blotting using FKTN antibody (RY213). Immunoreactive
bands were visualized using a chemiluminescence detection system (Perkin Elmer or
Amersham Biosciences Corp.) and an LAS3000 luminescent image analyzer (Fuji
Film). Uncropped and unprocessed full scan images are shown in Supplementary
information (Supplementary Fig. 14).
Microarray analysis. Microarray analysis was performed with an Agilent gene
expression microarray platform (SurePrint G3 Mouse Gene Expression 8 × 60 K).
We visualized genes with the largest variance using a hierarchical clustering
heatmap. For each gene, we compared expression levels between ﬂoxed and Fktn-
cKO RNAs. Gene expression differences were evaluated using the eBayes function
in the limma package66, microarray data were ﬁt to a linear model, and differential
expression was estimated by empirical Bayes moderation. The resulting P-values
were corrected via the Benjamini and Hochberg method using the topTable
function. Differentially expressed genes were deﬁned as those with Log2 changes of
at least 1.5-fold between a pair of samples at an FDR of 0.001 for genes. Supple-
mentary Table 1 provides the complete dataset. For differentially expressed genes,
we carried out functional annotation analysis using DAVID. Differentially
expressed genes were used as the input gene list, and all mouse genes that were
expressed in the heart were used as the background. We looked for enrichment of
genetic associations within KEGG pathways. Enrichment pathways were analyzed
using ReactomePA.
Data analysis. Data were analyzed by individuals who were blinded to the
genotype, drug treatment, and operation. Data presented here were reproducible
in at least three independent experiments. Results are shown as the means ± s.e.
m. Paired data were evaluated using a Student’s t-test. For multiple comparisons,
analyses of variance with Tukey–Kramer tests were performed as appropriate
using GraphPad Prism. The Kaplan–Meier method, with a log-rank test, was
used for survival analysis. A P value of < 0.05 was considered statistically
signiﬁcant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the ﬁndings of this study are available from the corresponding
author upon reasonable request. The source data underlying Figs. 1e, 3c, 4c, 4e, and 8b, d
are provided as Source Data ﬁle. The gene expression data were deposited at NCBI’s
Gene Expression Omnibus (GEO). It is accessible through GEO series accession number
of GSE138280.
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